Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05329545 · ClinicalTrials.gov registry record · Phase 3
Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
A Phase 3 study, sponsored by Mersana Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT05329545 is a Phase 3 study that was terminated before completion, run by Mersana Therapeutics. The registered enrollment target is 20 participants.
The verdict
NCT05329545, a Phase 3 study, was terminated before completion, sponsored by Mersana Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
UP-NEXT is a double-blind, randomized, placebo-controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks in patients with recurrent, platinum-sensitive high-grade serous ovarian cancer (HGSOC), including fallopian tube and primary peritoneal cancer, expressing high levels of NaPi2b.
Interventions
- OTHER Placebo
- DRUG Upifitimab rilsodotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-06-23 |
| Est. Completion | 2023-09-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05329545
The ClinicalTrials.gov registry entry for NCT05329545 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mersana Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05329545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05329545 about?
NCT05329545 is a clinical study titled "Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)". UP-NEXT is a double-blind, randomized, placebo-controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks in patients with recurrent, platinum-sensitive high-grade serous ovarian cancer (HGSOC), including fallo...
What is the current status of trial NCT05329545?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2022-06-23. Estimated completion is 2023-09-29.
What interventions are being tested in trial NCT05329545?
The interventions under investigation include: Placebo (OTHER), Upifitimab rilsodotin (DRUG).
Who is sponsoring clinical trial NCT05329545?
This trial is sponsored by Mersana Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.